JNJ

227.25

-0.15%↓

ABT

91.51

-2.44%↓

MDT

79.31

-3.13%↓

111.1

-3.26%↓

VEEV

158.34

-0.04%↓

JNJ

227.25

-0.15%↓

ABT

91.51

-2.44%↓

MDT

79.31

-3.13%↓

111.1

-3.26%↓

VEEV

158.34

-0.04%↓

JNJ

227.25

-0.15%↓

ABT

91.51

-2.44%↓

MDT

79.31

-3.13%↓

111.1

-3.26%↓

VEEV

158.34

-0.04%↓

JNJ

227.25

-0.15%↓

ABT

91.51

-2.44%↓

MDT

79.31

-3.13%↓

111.1

-3.26%↓

VEEV

158.34

-0.04%↓

JNJ

227.25

-0.15%↓

ABT

91.51

-2.44%↓

MDT

79.31

-3.13%↓

111.1

-3.26%↓

VEEV

158.34

-0.04%↓

Strona główna・Stock List・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Closed

SectorHealthcare

14.49 0.21

Buy Sell

Overview

Share price change

24h

Current

Min

14.49

Max

14.49

Key metrics
By Trading Economics
Income	-16M 1.7M
Sales	16M 185M
Profit margin	0.912
Employees	511
EBITDA	-31M 16M

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	51M 4.5B
Previous open	14.28
Previous close	14.49

News Sentiment

By Acuity

50%

177 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

5.925 / 7.38 Support & Resistance

Amicus Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 gru 2025, 14:38 UTC

Earnings

Hot Stocks

Stocks to Watch Friday: Nike, Oracle, FedEx, Sony -- WSJ

Peer Comparison

Price change

Amicus Therapeutics Inc Forecast

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Amicus Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.925 / 7.38Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

177 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.